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Cancer of the urinary bladder is the ﬁfth most common neoplasm in the industrialized countries. Diagnosis and surveillance are
dependent on invasive evaluation with cystoscopy and to some degree cytology as an adjunct analysis. Nomuscle invasive bladder
cancer is characterized by frequent recurrences after resection, and up to 30% will develop an aggressive phenotype. The journey
towards a noninvasive test for diagnosing bladder cancer, in order to replace or extend time between cystoscopy, has been ongoing
for more than a decade. However, only a handful of tests that aid in clinical decision making are commercially available. Recent
reports of DNA methylation in urine specimens highlight a possible clinical use of this marker type, as high sensitivities and
speciﬁcities have been shown. This paper will focus on the currently available markers NMP22, ImmunoCyt, and UroVysion as
well as novel DNA methylation markers for diagnosis and surveillance of bladder cancer.
1.Introduction
Cancer of the urinary bladder is the ﬁfth most common
neoplasm in the industrialized countries and in the Unites
States, with an estimated 70,530 new cases of bladder cancer
diagnosed and with 14,680 deaths in 2010 [1]. Risk factors
associated with the development of bladder cancer are main-
ly smoking and to a lesser extent workplace exposure to
carcinogens [2, 3]. No genomic risk markers have been dis-
covered apart from a few SNPs with a very low increase in
relative risk [4].
Inapproximately70%ofallcasesthepatientswillpresent
with nonmuscle invasive bladder cancer (NMIBC) of stages
Ta, T1, or Tis, whereas the remaining 30% of the tumors
will be muscle invasive stage T2–4 bladder cancers (MIBC).
Tumor recurrences are frequent (70%) in patients with
NMIBC, whereas progression to MIBC is less frequently ob-
served (10%–30%) [5]. The standard treatment of NMIBC
is transurethral resection (TUR) complemented by use of
intravesical immunotherapy or chemotherapy in order to
preclude recurrence and progression [6]. Risk factors asso-
ciated with recurrence are tumor size, multiplicity, stage, and
grade,whereastheriskfactorsforprogressionaretumorsize,
multiplicity,stage,highgrade,andthepresenceofcarcinoma
in situ (CIS) [7]. The sensitivity of cystoscopy for NMIBC is
close to 80% for white light cystoscopy and 96% when using
hexaminolevulinate(HAL).Thesensitivityofwhitelightcys-
toscopy decreases to 48% and 68% for detection of dysplasia
and CIS, respectively, whereas the sensitivity of cystoscopy
using HAL for these lesions remains in the range of 93%
to 95% [8, 9] .T h eh i g hr e c u r r e n c er a t er e q u i r e sf r e q u e n t
and prolonged surveillance by cystoscopy and makes bladder
cancer the most expensive cancer to treat overall [10, 11].
According to the EAU Guidelines on NMIBC, the current
treatment regime for low risk NMIBC patients is cystoscopy
at 3 months after TUR, and if negative, then the next
cystoscopy is advised done 9 months later and then yearly
for 5 years [6]. For high risk NMIBC and CIS patients the
standard surveillance is cystoscopy and urinary cytology at 3
months, and if negative, this is repeated every three months
for 2 years, then half-yearly for up to 5 years, and then yearly
[6]. In patients with an intermediate risk of progression,
surveillance is in between that advised for the followup for
low- and for high-risk patients [6]. Cytology is a noninvasive2 Advances in Urology
Table 1: Sensitivity and speciﬁcity of cytology, NMP22, ImmunoCyt, and UroVysion when no distinguishment is made between patients
with suspicion of bladder cancer and patients previously diagnosed with bladder cancer.
Test Samples/studies Sensitivity, %
(95% CI)
Speciﬁcity, %
(95% CI)
Interference by other
bladder conditions Comments Reference
Cytologya 14260/36 44 (38–51) 96 (94–98) Yes Subjective judgement [12]
NMP22b 10119/28 68 (62–74) 79 (74–84) Yes Cutoﬀ was ≥10U/mL for positive test
result [12]
ImmunoCyt 2896/8 84 (77–91) 75 (68–83) Yes At least one green or one red
ﬂuorescent cell [12]
UroVysion 2535/12 76 (65–84) 85 (78–92) No Cutoﬀs may vary between studies [12]
aVoided urine only.
bIncluding ﬁve studies using NMP22 BladderChek.
operator-dependent test often used in combination with
cystoscopy, owing to a very high speciﬁcity of 96% (94–98;
95% CI), but with a low average sensitivity of 44% (38–51,
95% CI). Cytology has higher sensitivity for high-stage and
high-grade tumors than for low-stage and low-grade tumors
[12].
The perfect urinary marker of bladder cancer should
reliably detect all tumors for the well-being of the patients
and at the same time have a very high speciﬁcity to minimize
false positive results. This is especially true when considering
screening in general, but also when considering screenings
of high risk groups and patients under suspicion of bladder
cancer. Six markers are approved by the U.S. Food and
Drug Administration (FDA) for diagnosis of bladder cancer
in patients suspected of having bladder cancer, or for
surveillance of bladder cancer. While they are all more
sensitive than cytology, they are unable to replace cystoscopy.
This paper will list the performance of cytology, the FDA-
approved biomarkers NMP22, ImmunoCyt, and UroVysion,
and investigational methylation urinary markers for the di-
agnosis and surveillance of bladder cancer. The performance
of methylation markers will be compared with cytology and
theFDA-approvedmarkers.Furthermore,thispaperwilldis-
cuss whether the urinary methylation markers may replace
cystoscopy, replace cytology as an adjunct to cystoscopy, or
postpone the time between cystoscopies in the surveillance
of NMIBC. Studies included in the review have been chosen
basedonthenumberofparticipantsincluded,andtheability
to determine whether primary lesions or recurrent lesions
have been studied in the papers.
2.Cytology
Urinarycytologyisthegoldstandardfornoninvasiveurinary
diagnosis of bladder cancer, and the cytological examination
is performed by a pathologist or cytologist who identiﬁes
cancer cells in the urine. The cells in the urine are classiﬁed
into one of four categories: normal, atypical/indeterminate,
suspicious, or malignant [13]. Urinary infections or other
inﬂammatory conditions of the bladder may produce false
positive results, and in addition the inter- and intraobserver
variability of cytology are both high [14, 15]. Cytology has
an overall test sensitivity of 44% (38–51, 95%CI) (Table 1),
but low-grade tumors (grades I and II) have a lower test
sensitivity than high-grade tumors. The test sensitivity of
l o w - g r a d et u m o r si s2 7 % ,w i t har a n g ef r o m0 %t o9 3 % ,
whereas high-grade tumors have a test sensitivity of 69%,
with a range from 0% to 100%. Pooled estimates from 36
studies including 14,260 patients have established that the
speciﬁcity of cytology is very high 96% (94–98; 95%CI) with
a low false-positive interpretation [12]. In patients with a
history of NMIBC the sensitivity is 38% (12–47; range) and
the speciﬁcity is 94% (83–97; range) (Table 2)[ 12].
3. Commercially Available Bladder
Cancer Markers
3.1. Nuclear Matrix Protein 22. The nuclear matrix protein
22 (NMP22) is a nuclear matrix protein that is found in
all cells. During mitosis, the NMP 22 protein is found in
the mitotic spindle, where it has an important role in the
distributionofchromatintodaughtercells[16,17].Thelevel
of NMP22 in bladder cancer cell lines has been shown to be
25-fold more concentrated than in the healthy urothelium
fromanormalbladder[18].Inpatientswithbladdertumors,
the NMP22 level was reported as 5 times greater than
in individuals with no bladder malignancies [19]. False
positive tests have been observed in individuals with benign
inﬂammatory conditions, and several other nonmalignant
conditions [20]. NMP22 was initially developed as a quanti-
tative assay (NMP22 test), but was later transformed into the
NMP22 BladderChek kit. The sensitivity and speciﬁcity of
the NMP22 tests, counting 10,119 patients in 28 studies, are
68%(62–74;95%CI)and94%(83–97; 95%CI),respectively
(Table 1). The NMP22 test has a higher sensitivity for high-
grade tumors than for low-grade tumors. The test sensitivity
for low-grade tumors is 50%, with a range from 0% to 86%,
whereas the test sensitivity is 83%, with a range from 0% to
100%, for high-grade tumors [12]. In patients with a history
of NMIBC, the test sensitivity is 69% (50–85; range) and the
speciﬁcity is 81% (46–93; range) (Table 2)[ 12].
3.2. ImmunoCyt. ImmunoCyt combines cytology with an
immunocytoﬂuorescence technique based on a cocktail of
monoclonalantibodieslabeledwithﬂuorescentmarkers.The
monoclonal antibodies recognize a high molecular weight
form of the carcinoembryonic antigen and two bladder
tumor cell-associated mucins. The analysis is performed inAdvances in Urology 3
Table 2: Performance of cytology and biomarkers in studies that include patients with suspicion of bladder cancer or patients previously
diagnosed with bladder cancer.
Test/marker Suspiciona/previousb
history of BC
Samples/
studies
Sensitivity, %
Median (range)
Speciﬁcity, %
Median (range) Reference
Cytology Suspicion 3331/7 44% (16–100) 96 (94–98) [12]
Previous history of BC 4495/6 38% (12–47) 94 (83–97)
NMP22 Suspicion 1893/4 71 (56–100) 86 (80–87) [12]
Previous history of BC 4284/7 69 (50–85) 81 (46–93)
ImmunoCyt Suspicion 280/1 85 88 [12]
Previous history of BC 326/1 81 75
UroVysion Suspicion 497/1 69 78 [12]
Previous history of BC 250/1 64 73
PMF1 Suspicion 118/1 65 95 [58, 62]
Previous history of BC
Myopodin Suspicion 164/1 65 80 [57]
Previous history of BC
I R F 8 ,p 1 4 ,a n ds F R P 1 Suspicion 45/1 85 95 [63]
Previous history of BC 4/1 100 —c
MYO3A, CA10, NKX6-2, DBC1, and
SOX11 or PENK
Suspicion 198/1 85 95 [64]
Previous history of BC 40/1 85 —
ZNF154, EOMES, HOXA9, POU4F2,
TWIST1, and VIM
Suspicion 79/1 98 100 [38, 65]
Previous history of BC 206/1 94 66
TWIST1 and NID2 Suspicion 278/1 90 93 [66]
Previous history of BC
RASSF1A, E-cadherin, Suspicion
[79] A P C ,D A P K ,M G M T ,B C L 2 ,h - T E R T ,
EDNRB, WIF1, TNFRSF25, and IGFBP3 Previous history of BC 40/1 86 8
APC, RASFF1A, RARB, DBC1, SFRP1,
SFRP2, SFRP4, SFRP5
Suspicion 146/1 52 100 [67]
Previous history of BC
SFRP1, SFRP2, SFRP4, SFRP5, VIF-1,
and DKK3
Suspicion 264/1 61.1 93.3 [50, 68]
Previous history of BC
RASSF1a, E-cad, and APC Suspicion 104/1 69 60 [39, 69]
Previous history of BC
APC a, TERT a, TERT b, and EDNRB Suspicion [80]
Previous history of BC 94 72 55
aOnly studies that include patients with a suspicion of bladder cancer.
bOnly studies that include patients with a previous history of bladder cancer.
cSpeciﬁcity in studies using healthy individuals as controls is not shown.
a laboratory and requires a large number of exfoliated cells
[21]. Applying a cut-oﬀ point of at least one green or one
red ﬂuorescent cell, the test sensitivity and speciﬁcity of the
ImmunoCyt assay with 2,896 participating patients in eight
studies are 84% (77–91; 95%CI) and 75% (68–83; 95%CI),
respectively(Table 1).Thetestsensitivityforlow-risktumors
is 81%, with a range from 55% to 90%, whereas high-risk
tumors have a test sensitivity of 90%, with a range from 67%
to 100% [12]. In patients with a history of NMIBC, the test
sensitivity is 81% and the speciﬁcity is 75% (Table 2)[ 12].4 Advances in Urology
3.3. UroVysion—Fluorescence In Situ Hybridization (FISH).
UroVysion is a multitarget ﬂuorescence in situ hybridization
(FISH) assay that utilizes DNA probes to identify aneuploidy
inchromosomes3,7,17,andlossofthe9p21locusoftheP16
tumor suppressor gene. The assay requires exfoliated cells in
the urine. The probe binds to the complementary DNA in
these cells, thereby visualizing the location of the targeted
chromosomes. The recommended cutoﬀ for a positive result
forbladdercancerisusuallydeﬁnedasﬁndingmorethanﬁve
urothelial cells with a gain of more than two chromosomes
or ten cells with a gain of a single chromosome, or 12 or
more cells with homozygous loss of the 9p21 locus. However,
the cutoﬀ may vary between institutions performing this
assay. Applying this cutoﬀ or a cutoﬀ very close to this, the
sensitivity and speciﬁcity of the ImmunoCyt assay with 2535
participating patients in 12 studies are 76% (65–84; 95%CI)
and 85% (78–92; 95%CI), respectively (Table 1). The test
sensitivity of low-risk tumors is 65%, with a range from 32%
to 100%, whereas high-risk tumors have a test sensitivity
of 95%, with a range from 50% to 100% [12]. In patients
with a history of NMIBC, the test sensitivity is 64% and the
speciﬁcity is 73% (Table 2)[ 12].
4. InvestigationalBladder Cancer Markers
Presently, there are several investigational urinary biomark-
ers of bladder cancer which are not yet commercially avail-
able, but the most promising will perhaps be approved as
urinary markers in the future. A noteworthy group of
these promising emerging markers is DNA methylation
markers. These markers have some advantages that make
them promising as tumor markers: (i) the DNA is quite
stable; (ii) methylation can be detected by sensitive real-time
PCR assays in a high through-put manner; (iii) results are
not dependent on subjective analysis. The remainder of this
paper will focus on DNA methylation markers and their
application for diagnosis and surveillance in bladder cancer.
4.1. DNA Methylation in Cancer. Cancer initiation and pro-
gression are driven by the accumulation of inherited or ac-
quired DNA alterations. These changes may be genetic or
epigenetic in nature [22]. Epigenetic changes are deﬁned
as heritable changes in gene function which do not involve
changes in DNA sequence. Although DNA methylation and
histone modiﬁcations (methylation, phosphorylation, acety-
lation) are all epigenetic modiﬁcations, only DNA methyla-
tion is included in the review. DNA methylation is, almost
exclusively, the attachment of a methyl group to the 5th
carbon in cytosine positioned just upstream of a guanosine
(CpG). Most CpG sites are sparsely distributed throughout
the genome and methylated, with the exception of CpG sites
locatedinclusters,termedCpGislands.ThemajorityofCpG
islands are unmethylated and located within the promoter
regionsandexon1ofmorethan50%ofallknowngenes[23–
25]. CpG dinucleotides outside CpG islands are generally
methylated in normal cells and undergo a substantial loss
of DNA methylation in cancers. Increased genetic instability
was observed in DNMT1 and DNMT3b double knock-out
cells [26] and cells with hypomorphic allele of DNA methyl-
transferase 1 [27]. Mechanisms linked to hypomethylation
induced genetic instability include decondensation of chro-
matinintorecombinationpermissiveconformation[28]and
activation of retrotransposon elements [29]. Furthermore,
hypomethylation of enhancer sites or other regulatory sites
repressed by methylation may trigger increased expression of
cancer promoting genes [22, 30, 31]. CpG sites within CpG
islands are usually in an unmethylated state, permissive to
transcription in normal cells, but become hypermethylated
at certain promoters in cancers. DNA methylation within
CpG islands, located in promoter regions, is involved in the
silencing of DNA transcription together with histone mod-
iﬁcations [32]. Development, genomic imprinting, and X-
chromosome inactivation are critical normal processes in
which DNA methylation occurs [33–35]. Alterations in
epigenetic control have been associated with several human
pathologic conditions including cancer [36].
4.2. DNA Methylation and Bladder Cancer: Tumor Tissue.
With the use of microarray technology, the number of genes
reported to be aberrantly methylated in bladder cancer tissue
isnowinthethousands[37,38].Ithasbeenshownthathigh-
risk tumors, generally, have more hypermethylated genes
than do low-risk tumors [37, 38]. Wolﬀ and colleagues
suggest two diﬀerent epigenetic pathways depending on
whether the tumor is muscle-invasive or not [37]. An
important ﬁnding for the use of methylation as a tumor
m a r k e rc o m e sf r o mas t u d yw i t h1 0p a t i e n t s .As t u d yo f
metachronous tumors from these 10 patients indicated that
the change in tumor methylation from normal urothelium
was stable within patients [38]. Multiple studies by separate
groups present data that aberrant methylation is associated
with the stage and grade of the tumors, as well as the recur-
rence rate and risk of progression [38–48]. Transcriptional
inactivation by CpG island promoter hypermethylation is
a well-established mechanism for gene silencing in cancer
including bladder cancer [46, 49–58]. Many genes have
been reported aberrantly methylated in bladder cancer, but
relatively few of the genes have been characterized with
respect to the function of the attendant gene silencing.
Age-dependent methylation of CpG islands occurs in a
tissue-speciﬁc manner in normal appearing tissue [59, 60],
and in bladder cancer increased methylation of CpG islands
has been reported to be associated with high age of the
patients [44, 61]. Examples of CpG islands in which methy-
lation is associated with high age include CCNA1, PGP9,
and CCND2 [44]. These ﬁndings make it of paramount
importance to include age-matched controls when identify-
ing diagnostic DNA methylation markers for bladder cancer.
5. DNA Methylation and Bladder Cancer:Urine
5.1. Diagnosis of Urothelial Carcinoma of the Bladder. Several
studies have reported results indicating that methylation
markers, applied to DNA from voided urine or bladder
washes, can be used for the diagnosis of bladder cancer
(Table 3). Nine studies presented results from patients withAdvances in Urology 5
Table 3: Performance of DNA methylation markers in studies that include patients with suspicion of bladder cancer and patients previously
diagnosed with bladder cancer.
Test Method Patientsa/
studies Sensitivity, % Speciﬁcity, % Interference by other
bladder conditions Reference
PMF1 MSP 118/1 65 95 No [58, 62]
Myopodin MSP 164/1 65 80 No [57]
RASSF1A MSP 24/1 50 100 Not done [70]
DAPK, RARβ, E-cadherin, and p16 MSP 39/1 91 76 Not done [71]
IRF8, p14, and sFRP1 qMSP 49/1 87 95 No information [63]
MYO3A, CA10, NKX6-2, DBC1, and
SOX11 or PENK qMSP 238/1 85 95 No [64]
GDF15, TMEFF2, and VIM qMSP 110/1 94 90 Not done [72]
APC, RASSF1A, and p14ARF MSP 66/1 87 100 No [73]
DAPK, BCL2, and TERT qMSP 57/1 78 100 Not done [42, 74]
CDKN2A, ARF, MGMT, and GSTP1 qMSP 269/1 69 100 No [41, 75]
RASSF1A, p14, and E-cadherin MSP 66/1 80 100 Not done [76]
ZNF154, HOXA9, POU4F2, and
EOMES
MS-
HRM 174/1 84 96 No [38, 65]
TWIST1 and NID2 qMSP 278/1 90 93 No [66]
APC, RASFF1A, RARB, DBC1, SFRP1,
SFRP2, SFRP4, SFRP5 qMSP 146/1 52 100 No [67]
SFRP1, SFRP2, SFRP4, SFRP5, VIF-1,
and DKK3 MSP 264/1 61.1 93.3 Not done [50, 68]
BCL2 and hTERT qMSP 213/1 76 98 No [21]
RASSF1a, E-cad, and APC qMSP 104/1 69 60 No [39, 69]
SALL3, CFTR, ABCC6, HPR1,
RASSF1A, MT1A, RUNX3, ITGA4,
BCL2, ALX4, MYOD1, DRM, CDH13,
BMP3B, CCNA1, RPRM, MINT1, and
BRCA1
MSP 159/1 92 88 No [77]
aIncluding both patients with BC and individuals with no history of bladder cancer.
bNot applicable.
a suspicion of bladder cancer [57, 62–69], whereas other
studies included a mixture of samples from patients with
a suspicion of bladder cancer, and patients previously
diagnosed with bladder cancer, or the information was not
reported [21,38,70–77].Patientswithaconﬁrmedsuspicion
of bladder cancer will generally have larger tumors that shed
more cells into the urine than patients under surveillance
for bladder cancer. Cancer cells shed from tumors within the
bladder may be of low or high grade. Low-grade tumors are
lesslikelytoshedmanycellsintotheurineastheirhigh-grade
counterparts because the high-grade tumors have weaker
intercellular attachments [78]. Depending on the detection
method this may inﬂuence the sensitivity of the urinary
markers.
The large variation of cell types in the urine necessitates
that the DNA methylation markers are cancer speciﬁc and
uninﬂuenced by hematuria, bladder infections, or other be-
nign bladder conditions. Many of the studies have included
individuals with a mixture of benign urothelial conditions
to insure the cancer speciﬁcity of the methylation markers,
although some studies have either not done this or were not
reported.
The ﬁrst study demonstrating the feasibility of diagnos-
ing bladder cancer through methylation using DNA from
voided urine came from Chan and colleagues in 2002 [71].
They analyzed urine sediments from voided urine from 22
patients and 17 age- and sex-matched controls by methy-
lation sensitive PCR (MSP). The analysis was based on a
panel of markers (DAPK, RARβ, E-cadherin, and p16) that
achieved a sensitivity of 91% and a speciﬁcity of 76% (Table
3)[ 71]. In the same study, the sensitivity and speciﬁcity of
cytology were 46% and 100%, respectively. Subsequently,
m a n ys t u d i e sh a v er e p o r t e dm e t h y l a t i o nm a r k e r sw i t ha n
increased sensitivity, but a lower speciﬁcity than cytology.
Investigations of matched tumor and urine samples showed
no false positive urine samples when the tumor was negative
for methylation, indicating the speciﬁcity of the markers.
Unfortunately, Chan et al. did not provide any information
about bladder conditions within the control group.
The fact that DNA methylation markers may be as spe-
cific as cytology was revealed in a study by Dulaimi et al.
with 45 bladder cancer patients and 21 healthy age-matched
individuals including 9 individuals with cystitis. The sensi-
tivity was only 87%, but the speciﬁcity was 100% (Table 3).6 Advances in Urology
The concordance between methylation in the tumor and
the matched urine was very high, and no urine sample was
positive without simultaneous tumor methylation [73].
Quantitative real-time PCR was introduced by Friedrich
et al., who investigated 37 bladder cancer patients undergo-
ing radical cystectomy, 10 age-matched cancer-free individu-
als,and10non-age-matchedcancer-freeindividuals.Apanel
of markers (DAPK, BCL2, and TERT) achieved a sensitivity
of 78% and a speciﬁcity of 100% (Table 3)[ 74]. Currently,
real-time PCR is the most applied technique, owing to the
low DNA requirement and high sensitivity, compared with
MSP.
AdiﬀerenttechniquewasappliedbyReinertandcowork-
ers when they used methylation-sensitive high-resolution
melting (MS-HRM) PCR to study voided urine from 119
bladder cancer patients and 59 individuals with no history
of bladder cancer. The controls were from patients with
benignprostatichyperplasia(BPH)orbladderstones,and19
patients were suspected of having a bacterial infection. In
that study, a four-marker panel (ZNF154, HOXA9, POU4F2,
and EOMES) achieved a sensitivity of 84% and a speciﬁcity
of 96% (Table 3)[ 38]. Recently, a validation of ZNF154,
HOXA9, POU4F2, and EOMES by real-time PCR (Methy-
Light) using DNA from 184 bladder cancer patients and 35
control individuals resulted in an increased sensitivity of the
individual markers by eight to twenty-ﬁve percentage points
(Table 2)[ 38, 65]. The increased test sensitivity is probably
due to more sensitive MethyLight primers, as the patient
cohorts are comparable.
Notably, a prospective multicenter study with both train-
ing and validation sets with a total of 83 bladder cancer pa-
tients and 178 individuals with no history of bladder cancer
achieved a sensitivity of 90% and a speciﬁcity of 93%. The
control patients were all diagnosed with benign urologic
diseases (Table 2)[ 66].
Several additional studies have conﬁrmed that urinary
markers may be highly sensitive for the detection of bladder
cancer and at the same time very speciﬁc, even when exam-
iningpatientswithotherurologicaldiseases(Table 3).Lately,
numerous methylation markers identiﬁed by screening of
bladder cancer tissue samples or cell lines show high
sensitivity and speciﬁcity when translated to BC detection in
urine[38,64,66,72,77].Bladdermarkerstudiesrequireage-
matched controls to ensure that the observed methylation is
tumor speciﬁc, since methylation within CpG islands may
increase with age in a tissue-speciﬁc manner [60]. Most
studies have included age-matched controls, but in the study
by Lin et al. the median age between bladder cancer patients
and healthy individuals varied by more than 30 years [76].
Many studies have reported a high concordance between
tumor tissue and urine specimen methylation, indicating
that the methylation detected was speciﬁc for bladder cancer
cells and did not reﬂect methylation of DNA from other
sources in the urinary system [21, 38, 67, 70–73, 75–77,
81]. Deviating from this was Vinci et al. who found the
methylation status of DAPK to be discordant between tumor
and urine sediments [21]. Several methylation markers have
shown higher sensitivity with increasing stage [21, 38, 68, 75,
81]a n dg r a d e[ 21, 38, 65, 70, 81]. Two studies have reported
that the methylation markers reported in their studies were
not independent of each other [38, 75]. This indicates that
one single methylation mechanism may account for the
majority of the methylation alterations analysed in those
studies.
Methylationmarkersforbladdercancerdiagnosisarestill
at an early stage compared with the FDA approved markers.
Most of the reported markers have been tested on cohorts
that varied greatly between studies. In addition to this, many
markers are lacking validation in independent prognostic
experimentswithpredeterminedcut-oﬀvalues.Independent
validation experiments will often achieve lower test sensitiv-
ity and/or lower test speciﬁcity, as the cut-oﬀ values from
the initial experiment were ﬁtted to the data. With that
said, comparing the methylation markers with cytology, it
is evident that the methylation markers are more sensitive
than cytology, and for the some of the markers the speciﬁcity
is even comparable with cytology (Table 2). Nevertheless,
methylation markers have not entered the clinical setting as
diagnosticmarkersofbladdercancerinsteadofcystoscopyor
as a supplement to cystoscopy or cytology.
5.2. Urinary DNA Methylation Markers for Surveillance of
Bladder Cancer. Patients previously diagnosed with bladder
cancer are included in a treatment regimen with frequent
follow-up cystoscopy examinations, and perhaps cytology as
an adjunct. Cystoscopy is an invasive procedure that is costly
for the healthcare system and unpleasant for the patient.
The search for a noninvasive DNA methylation marker for
the diagnosis of bladder cancer was initiated more than a
decade ago by Chan and coworkers [71], whereas the search
for a diagnostic DNA methylation marker for surveillance
of bladder cancer patients only started in 2008 with a study
by Rouprˆ et et al. [79]. They designed a control group from
bladder cancer patients with a negative cystoscopy and/or
biopsies. In this small study with 40 patients of which 15
experienced a recurrence, they reported the sensitivity of an
11 gene panel to be 86%, while the speciﬁcity was as low as
8%(Table 2).InamorerecentstudybyZuiverloonetal.they
developed a four gene markers panel by screening NMIBC
tissue, urine from nonbladder cancer patients, and blood
from bladder cancer patients for methylation of 37 genes. In
the validation cohort with 94 bladder cancer patients under
surveillance, the sensitivity of this panel of urinary markers
was 72% and the speciﬁcity was 55% (Table 2)[ 80]. In a
most recent and yet unpublished study by Reinert et al. [65],
theytestedsixmethylationmarkersthathavepreviouslybeen
shown to be able to diﬀerentiate between bladder cancer
patients and individuals with no history of bladder cancer
with high sensitivity and speciﬁcity [38]. When including
only urine samples from patients that had previously tested
positive for methylation, and analyzing 206 voided urine
samples from patients under surveillance for bladder cancer,
theyachievedatestsensitivityof93%andaspeciﬁcityof47%
of a single marker when comparing to cystoscopy carried
out at the same visit to the clinic. Including cystoscopy
results during a 12-month follow-up period in the analysis,
they found many of the samples formerly classiﬁed as
false positives to be true positives (anticipatory positives).Advances in Urology 7
The adjusted methylation marker sensitivity and speciﬁcity
were 94% and 66%, respectively. Importantly, in these set-
tings all six markers were independent of stage and grade.
Anticipatory positives are results that show a positive
ﬁnding preceding visual evidence of a bladder tumor. The
term “anticipatory positive” is debatable, due to the high re-
currence rate in bladder cancer. However, a prognostic study
with 250 recurrent cases by Yoder and colleagues focusing
on anticipatory ﬁndings showed that of 148 patients with
negative cystoscopy, 5% of UroVysion negative and 65% of
UroVysion positive results experienced a recurrent urinary
cancer within 29 months after cystoscopy [82]. In a similar
manner, the anticipatory eﬀect has been shown for DNA
methylation markers by Reinert and colleagues, who found
that 4% of methylation-negative and 63% of methylation-
positive patients relapse within 12 months [65].
5.3. Urinary DNA Methylation Markers for Prediction of Re-
currence Free Survival. While several studies have focused on
diagnostic markersandmarkers ofsurveillance,the potential
of urinary methylation markers as prognostic markers of
recurrence has just recently been suggested in a single and
yet unpublished study by Reinert et al. [65]. They reported
that detection of DNA methylation of ZNF154, HOXA9,
POU4F2, TWIST1, or VIM was signiﬁcantly associated with
future recurrences, with hazard ratios ranging from 7.8 to
13.9. They speculated that the prognostic value of the meth-
ylation markers was connected with the existence of a DNA
hypermethylation ﬁeld disease as reported previously [37].
6. Conclusion
Early diagnosis of bladder cancer, and careful followup for
detection of recurrences after initial treatment, are main
tasks of current urological research. The high rate of recur-
rences and the prolonged followup by cystoscopy and cytol-
ogy make bladder cancer the most expensive cancer to treat,
overall. However, by utilizing noninvasive urinary markers,
it may be possible to improve the diagnosis of new cancers
as well as improve the management of NMIBC. NMP22,
UroVysion, and ImmunoCyt are well-examined urinary
markers. NMP22 and UroVysion are both FDA-approved
tests for initial diagnosis of bladder cancer in patients with
a suspicion of bladder cancer and for surveillance of bladder
cancer; however, ImmunoCyt is only approved for the
surveillance of bladder cancer in conjunction with urinary
cytology and cystoscopy. All three markers have a higher
sensitivity than cytology, but a lower speciﬁcity (Table 1).
Furthermore, the speciﬁcity of NMP22 and ImmunoCyt are
inﬂuenced by urinary conditions other than bladder cancer,
which makes them unusable in many situations (Table 1).
T h em e t h y l a t i o nm a r k e r sa r en o ta sw e l ls t u d i e da st h e
FDA-approved markers, and none have been approved by
the FDA for the diagnosis or surveillance of bladder cancer.
Weaknesses of the methylation studies include (1) many
small studies with a limited number of participants; (2)
diﬀerent methods for analyzing methylation between studies
making comparison of markers diﬃcult; (3) low homogene-
ity of study population regarding stage and grade of the
patients; (4) lack of information about adjuvant intravesical
therapy; (5) heterogeneous patients populations, as many
studiesincludepatientsundersuspicionforbladdercanceras
well as patients with a history of bladder cancer; (6) absence
ofage-andsex-matchedreferencegroups;(7)retrospectively
collected samples that may be biased regarding availability of
material for analysis. With these reservations in mind, most
methylation markers show higher sensitivity than cytology,
but often at the cost of a lower speciﬁcity (Table 2). For
diagnosis of bladder cancer in patients under suspicion
of bladder cancer, the most sensitive and speciﬁc DNA
methylation markers are probably preferable compared with
the FDA-approved markers, owing to the higher sensitivity
and speciﬁcity of the methylation marker, in addition to
the fact that most of the DNA methylation markers have
been shown to be uninﬂuenced by other benign bladder
conditions or benign prostatic hyperplasia.
For surveillance of bladder cancer patients, DNA methy-
lation markers have the highest sensitivity (94%) followed by
ImmunoCyt (81%), NMP22 (69%), UroVysion (64%), and
cytology (38%). Cytology has the highest speciﬁcity (94%)
followed by NMP22 (81%), ImmunoCyt (75%), UroVysion
(73%), and DNA methylation markers (66%). In situations
where high test sensitivity is important, DNA methylation
markersoughttobethetestofchoice,whereasifahighspeci-
ﬁcity is important, cytology should be the preferred marker.
Considering the question whether or not a urinary marker
maypostponethetimebetweencystoscopiesorreplacecytol-
ogy in surveillance of NMIBC, the answer must be that some
of the methylation markers are more than capable, because
the DNA methylation markers have higher sensitivity than
white light cystoscopy and cytology. This assumes that the
current results can be validated in independent prognostic
studies. In addition, it will be important to have some
comparison studies in which the DNA methylation markers
are compared with established markers using standardized
assays and cut-oﬀ values. In a study by Yossepowitch et al.
they conclude that 75% of patients under surveillance for
bladder cancer would accept the result of a urine marker
test as a replacement for cystoscopy, if the sensitivity of
the marker was at least 95% [83]. It is worth considering
that the patients interviewed were expecting the sensitivity
of cystoscopy to be 100%, which is not true in all cases.
A suggested surveillance regime for low- and medium-risk
NMIBC could be to replace the cystoscopies at 12, 24, and
48 months, after the removal of the tumor, with methylation
markers(Figure 1).Thepotentialofthemethylationmarkers
is unmatched by cytology and the FDA-approved markers
with respect to detecting recurrent tumors. However, until
additional prospective studies of suitable proportions have
validated the promising results, surveillance will continue to
consist of cystoscopy and cytology.
7.FuturePerspectives
Detecting bladder cancer using diagnostic or surveillance
markers remains a challenge, as none of the currently
approvedmarkerscanreplacecystoscopyorprolongthetime
between cystoscopies. The ﬁeld of methylation biomarkers is8 Advances in Urology
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Figure 1: Follow-up model for low- and medium-risk NMIBC in
which methylation markers were applied to prolong time between
cystoscopies.
promising,butrequiresmoreprospectivemulticenterstudies
that explicitly clarify the purpose of the study as screening,
diagnosis of primary disease, or surveillance. In addition,
thesestudiesshouldincludetheappropriatepatientsinorder
to validate the current ﬁndings in an unbiased manner.
Currently, at least one such study combining methylation
markers and FGFR3 mutational markers for surveillance
of bladder cancer is ongoing (UROMOL, FP7 EU study).
This study investigates urine samples from more than 1200
patients with bladder cancer in several clinical centers in
Europe.
Recent technological advances within the ﬁeld of methy-
lation analysis, like the Illumina Inﬁnium HumanMethyla-
tion450 BeadChip, or some of the many next generation
sequencing-based methylation analyses, for example, whole-
genome shotgun bisulﬁte sequencing, may uncover even
more sensitive and speciﬁc markers in the future. Neverthe-
less, the emphasis should be to develop existing markers and
in parallel identify new promising methylation markers in
order to increase survival and the quality of life for bladder
cancer patients.
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